Dr. Niels W.C.J. van de Donk (VU University Medical Center—Amsterdam, Netherlands) compares the efficacy of Teclistimab versus current treatments in patients with triple-class exposed relapsed/refractory multiple myeloma
Abstract Title:
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-world Clinical Practice in the Prospective LocoMMotion Study in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
What is the purpose of the study:
Prognosis and often cycle through several treatments, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies.
Teclistamab is a T-cell redirecting bispecific antibody targeting B-cell maturation antigen ×CD3 currently being evaluated in the multicohort phase 1/2 MajesTEC-1 (NCT04557098) trial in patients with RRMM who had received ≥3 prior lines of therapy (LOT) and were triple-class exposed (TCE).
Conclusion:
Teclistamab showed significantly improved response outcomes in addition to OS, PFS, and DOR compared with real-world physician’s choice of therapy in patients with TCE RRMM who received ≥3 prior lines of therapy.
Doctor Bio:
Niels van de Donk MD, PhD is a Hematologist and Professor of Hematology at VU University Medical Center in Amsterdam, Netherlands. Prof. van de Donk is a reviewer for several top journals, including Blood, Leukemia, and Haematologica, as well as associate editor of the Netherlands Journal of Hematology and secretary of the HOVON multiple myeloma working party. In 2017, Prof. van de Donk was awarded the prestigious Swammerdam prize by the Dutch Society of Hematology for his contributions to hematology/oncology as a young researcher.
with support from:
Bristol Myers Squibb, Janssen, and Takeda Oncology
